Recombinant Human OTC Protein，His

The research on OTC (ornithine transcarbamylase) recombinant proteins stems from the need to address urea cycle disorders, particularly ornithine transcarbamylase deficiency. OTC is a crucial enzyme located in the mitochondria of liver cells, responsible for converting ornithine and carbamoyl phosphate into citrulline, a vital step in the urea cycle that helps detoxify ammonia in the body. Genetic mutations can impair OTC function, leading to the accumulation of ammonia, which poses severe health risks, especially in newborns and young children. Current management strategies focus on lifetime dietary restrictions and ammonia scavengers, but these approaches do not address the underlying enzyme deficiency. Researchers are exploring the potential of recombinant protein therapy to restore normal OTC levels in affected individuals. This involves the production of genetically engineered OTC proteins using systems like E. coli or yeast, allowing for the generation of a therapeutic product that can be administered to patients. Preclinical and clinical studies have shown promise in evaluating the safety and efficacy of these therapies, paving the way for potential breakthroughs in treating OTC deficiency. By advancing understanding in this field, researchers aim not only to improve the quality of life for patients but also to mitigate the long-term neurological damage associated with untreated conditions. Overall, the quest for effective OTC recombinant protein therapies highlights the intersection of genetic research, protein engineering, and clinical application in the fight against inherited metabolic disorders.